array(3) { ["company_details"]=> array(13) { ["name"]=> string(28) "Bristol-Myers Squibb Company" ["slug"]=> string(37) "81631-us-bristol-myers-squibb-company" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/7b41874f-2658-484b-890c-9b9bd5a41f13" ["description"]=> string(1400) "At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html" ["address_street"]=> string(19) "430 E 29TH St FL 14" ["address_place"]=> string(8) "New York" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1887-02-28" ["website_domain"]=> string(7) "bms.com" ["website_url"]=> string(19) "https://www.bms.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(1200) ["article_count"]=> int(2495) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(63) "Hardly any impetus for Bristol-Myers Squibb shares (€45.8204)" ["snippet_en"]=> string(96) "Little price movement at the moment for Bristol-Myers Squibb shares. The paper last cost $50.21." ["url"]=> string(89) "https://www.ariva.de/news/kaum-impulse-fr-die-bristol-myers-squibb-aktie-45-8204-11111849" ["image_url"]=> string(78) "https://images.businessradar.com/articles/5ea000b9-f0a7-49bf-92bb-c509ca61c90b" ["source"]=> string(8) "ariva.de" ["publication_date"]=> string(10) "2024-01-12" ["categories"]=> array(4) { [0]=> string(15) "Market Movement" [1]=> string(12) "Stock Market" [2]=> string(16) "Share Repurchase" [3]=> string(14) "Issuing Shares" } } [1]=> array(7) { ["title_en"]=> string(65) "Aurinia Pharmaceuticals shares surge on Gilead acquisition rumors" ["snippet_en"]=> string(65) "Aurinia Pharmaceuticals shares surge on Gilead acquisition rumors" ["url"]=> string(108) "https://in.investing.com/news/aurinia-pharmaceuticals-shares-surge-on-gilead-acquisition-rumors-93CH-3908497" ["image_url"]=> NULL ["source"]=> string(13) "investing.com" ["publication_date"]=> string(10) "2023-11-21" ["categories"]=> array(7) { [0]=> string(25) "Business Model Resilience" [1]=> string(15) "Market Movement" [2]=> string(12) "Stock Market" [3]=> string(14) "Issuing Shares" [4]=> string(9) "Investors" [5]=> string(11) "Acquisition" [6]=> string(24) "Stock Research & Ratings" } } [2]=> array(7) { ["title_en"]=> string(69) "Bristol-Myers Squibb (NYSE:BMY) Shares Sold by London Co. of Virginia" ["snippet_en"]=> string(212) "London Co. of Virginia trimmed its position in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 5.2% during the first quarter, according to the company in its most recent Form 13F filing with the SEC." ["url"]=> string(109) "http://www.defenseworld.net/2023/09/11/bristol-myers-squibb-nysebmy-shares-sold-by-london-co-of-virginia.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/cb1db1c2-2bfd-4fa7-82ac-474851592635" ["source"]=> string(16) "defenseworld.net" ["publication_date"]=> string(10) "2023-09-11" ["categories"]=> array(7) { [0]=> string(18) "General Investment" [1]=> string(12) "Stock Market" [2]=> string(14) "Issuing Shares" [3]=> string(31) "Financial Update/Profit Warning" [4]=> string(11) "Regulations" [5]=> string(24) "Quarterly/Annual Figures" [6]=> string(24) "Stock Research & Ratings" } } [3]=> array(7) { ["title_en"]=> string(130) "S&P 500 shares Bristol-Myers Squibb shares: This is how much profit an early investment in Bristol-Myers Squibb would have brought" ["snippet_en"]=> string(96) "Invested in Bristol-Myers Squibb shares years ago: This is how much investors would have earned." ["url"]=> string(175) "https://www.finanzen.ch/nachrichten/aktien/s-p-500-titel-bristol-myers-squibb-aktie-so-viel-gewinn-haette-ein-fruehes-investment-in-bristol-myers-squibb-eingebracht-1032605644" ["image_url"]=> string(78) "https://images.businessradar.com/articles/c9962130-4aac-43e3-a5e9-bef9f2cb7ffe" ["source"]=> string(11) "finanzen.ch" ["publication_date"]=> string(10) "2023-09-05" ["categories"]=> array(4) { [0]=> string(18) "General Investment" [1]=> string(12) "Stock Market" [2]=> string(14) "Issuing Shares" [3]=> string(31) "Financial Update/Profit Warning" } } [4]=> array(7) { ["title_en"]=> string(62) "Bristol-Myers Squibb (NYSE:BMY) Stock Holdings Raised by Tobam" ["snippet_en"]=> string(296) "Tobam grew its position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 102.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 589,574 shares of the biopharmaceutical company's stock after b" ["url"]=> string(73) "https://www.marketbeat.com/instant-alerts/nyse-bmy-sec-filing-2023-07-24/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/24d8e382-c956-4b20-a5c8-680afaec2c82" ["source"]=> string(14) "marketbeat.com" ["publication_date"]=> string(10) "2023-07-24" ["categories"]=> array(3) { [0]=> string(18) "General Investment" [1]=> string(12) "Stock Market" [2]=> string(14) "Issuing Shares" } } [5]=> array(7) { ["title_en"]=> string(68) "Immatics: 35 Million. USD-Capital Transfer of Bristol Myers Squibb -" ["snippet_en"]=> string(115) "Immatics: Bristol Myers Squibb's $35M Equity Investment: BMS to Acquire Over 2.4M Common Shares at $14.46 per share" ["url"]=> string(105) "https://www.goingpublic.de/life-sciences/immatics-35-mio-usd-kapitalbeteiligung-von-bristol-myers-squibb/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/90eb9310-cf1d-4fa4-bc4f-6db9a2942c32" ["source"]=> string(14) "goingpublic.de" ["publication_date"]=> string(10) "2023-07-24" ["categories"]=> array(2) { [0]=> string(11) "Acquisition" [1]=> string(14) "Issuing Shares" } } [6]=> array(7) { ["title_en"]=> string(67) "Bristol-Myers Squibb Co. Shares Approach 52-Week Low - Market Mover" ["snippet_en"]=> string(226) "Bristol-Myers Squibb Co. (BMY) shares closed today at 1.6% above its 52 week low of $63.07, giving the company a market cap of $136B. The stock is currently down 8.5% year-to-date, down 16.5% over the past 12 months, and up 37" ["url"]=> string(97) "https://www.nasdaq.com/articles/bristol-myers-squibb-co.-shares-approach-52-week-low-market-mover" ["image_url"]=> NULL ["source"]=> string(10) "nasdaq.com" ["publication_date"]=> string(10) "2023-06-28" ["categories"]=> array(1) { [0]=> string(14) "Issuing Shares" } } [7]=> array(7) { ["title_en"]=> string(65) "Css LLC Il Acquires 500 Shares of Bristol-Myers Squibb (NYSE:BMY)" ["snippet_en"]=> string(216) "Css LLC Il lifted its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 3.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC)." ["url"]=> string(106) "http://www.defenseworld.net/2023/06/13/css-llc-il-acquires-500-shares-of-bristol-myers-squibb-nysebmy.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/c45f9f00-9127-4aea-91d9-0be35774b684" ["source"]=> string(16) "defenseworld.net" ["publication_date"]=> string(10) "2023-06-13" ["categories"]=> array(3) { [0]=> string(12) "Stock Market" [1]=> string(14) "Issuing Shares" [2]=> string(24) "Stock Research & Ratings" } } [8]=> array(7) { ["title_en"]=> string(63) "Bristol-Myers Squibb Co. Shares Near 52-Week Low - Market Mover" ["snippet_en"]=> string(226) "Bristol-Myers Squibb Co. (BMY) shares closed today at 1.6% above its 52 week low of $64.41, giving the company a market cap of $139B. The stock is currently down 6.0% year-to-date, down 10.6% over the past 12 months, and up 47" ["url"]=> string(93) "https://www.nasdaq.com/articles/bristol-myers-squibb-co.-shares-near-52-week-low-market-mover" ["image_url"]=> NULL ["source"]=> string(10) "nasdaq.com" ["publication_date"]=> string(10) "2023-05-24" ["categories"]=> array(1) { [0]=> string(14) "Issuing Shares" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(254) } [1]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(163) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(151) } [3]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(94) } [4]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(89) } [5]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(76) } [6]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(74) } [7]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(64) } [8]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(63) } [9]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(60) } [10]=> array(2) { ["name"]=> string(6) "Merger" ["count"]=> int(60) } [11]=> array(2) { ["name"]=> string(17) "Energy Management" ["count"]=> int(56) } [12]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(54) } [13]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(47) } [14]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(47) } [15]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(45) } [16]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(45) } [17]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(42) } [18]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(39) } [19]=> array(2) { ["name"]=> string(25) "Business Model Resilience" ["count"]=> int(35) } [20]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(35) } [21]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(33) } [22]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(32) } [23]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(28) } [24]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(27) } [25]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(26) } [26]=> array(2) { ["name"]=> string(12) "Going Public" ["count"]=> int(24) } [27]=> array(2) { ["name"]=> string(10) "Divestment" ["count"]=> int(22) } [28]=> array(2) { ["name"]=> string(9) "Valuation" ["count"]=> int(21) } [29]=> array(2) { ["name"]=> string(15) "Blogs & Columns" ["count"]=> int(21) } } } 81631-us-bristol-myers-squibb-company